What turned a cancer researcher into a literature watchdog?

Jennifer Byrne

Sometime in the middle of 2015, Jennifer Byrne, professor of molecular oncology at the University of Sydney, began her journey from cancer researcher to a scientific literature sleuth, seeking out potentially problematic papers.

The first step was when she noticed several papers that contained a mistake in a DNA construct which, she believed, meant the papers were not testing the gene in question, associated with multiple cancer types.  She started a writing campaign to the journal editors and researchers, with mixed success. But less than two years later, two of the five papers she flagged have already been retracted.

When asked why she spent time away from bench research to examine this issue, Byrne told us:  Continue reading What turned a cancer researcher into a literature watchdog?

A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Last March, a PhD student at Harvard filed a misconduct allegation against his mentor, a prominent stem cell researcher. Three months later, he was taken from his home by police in the middle of the night for a forced psychiatric evaluation.

How did this happen? Continue reading A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

How to spot a “citation cartel”

Iztok Fister Jr

Do you know the difference between a group of researchers in the same field who cite each other’s related work, and a group of authors who purposefully cite each other in order to boost their own profiles? It’s not easy to do, say researchers in a new article about so-called “Citation cartels.” In Frontiers in Physics, Matjaz Perc and two Iztok Fisters (Senior and Junior) from the University of Maribor in Slovenia present an algorithm to help identify groups of researchers citing each other for overly collegial reasons. (For more on the phenomenon, see a recent column in STAT by our co-founders.) We spoke with first author Iztok Fister Jr.

Retraction Watch: What exactly are “citation cartels”? How do they differ from groups of researchers in the same field who tend to cite each other because their research is related in some way, without any nefarious intent? Continue reading How to spot a “citation cartel”

Breast cancer studies by fired Pfizer employee retracted

Last year, Pfizer fired one of its scientists following an investigation that ended with requests for retraction of five of her studies. Now, two of the five papers, which were first flagged on PubPeer, have been retracted.

One notice cites the Pfizer investigation, which found that cancer researcher Min-Jean Yin had included duplicated images in all five papers. Yin is the last author on both retracted papers.

Here’s the first notice from Clinical Cancer Research, which says most or all of the questioned images appear to be duplicates, and Pfizer — who sponsored the study and requested the retraction — can’t find the originals:
Continue reading Breast cancer studies by fired Pfizer employee retracted

“Crucial experiments” missing from retracted plant study

A 2016 study was retracted from a Frontiers journal after editors realized the authors had omitted experiments that didn’t support the hypothesis. 

Gearóid Ó Faoleán, ethics and integrity manager at Frontiers, which publishes Frontiers in Plant Science, told us:

In accordance with our complaints protocol, the Field Chief Editor led the investigation that resulted in the decision to retract the paper.

Here’s the retraction notice: Continue reading “Crucial experiments” missing from retracted plant study

Authors retract two statin papers, one with problems “too extensive to revise”

Researchers in China have retracted two 2016 papers about the possible use of a cholesterol-lowering agent to treat bleeding on the brain.

One of the retracted papers in the Journal of Neurosurgery (JNS) had multiple problems that were “too extensive to revise,” according to the lengthy retraction notice, relating to issues with authorship, data analyses, and patient enrollment. The notice is signed by first author Hua Liu of the Nanjing Medical University in China.

Liu is also the first author of another recently retracted paper in Frontiers in Neuroscience, pulled for incorrectly categorizing patients.

The JNS retraction notice begins: Continue reading Authors retract two statin papers, one with problems “too extensive to revise”

Watch out for predatory journals, and consider retract/replace, suggests medical journal group

Darren Taichman

The challenges facing science publishing are ever-evolving, and so too are the recommendations for how to face them. As such, the International Committee of Medical Journal Editors (ICMJE) frequently updates its advice to authors. In December, 2016, it made some notable changes – specifically, asking authors to pay closer attention to where they publish, in order to avoid so-called “predatory” journals, and encouraging more authors to consider “retracting and replacing” a paper with an updated version when the problems stem from honest error (something more journals have been embracing). We spoke with Darren Taichman, Executive Deputy Editor of the Annals of Internal Medicine and Secretary of the ICMJE, about the changes.

Retraction Watch: The first set of recommendations was issued in 1978 — how have they evolved, generally speaking, since then?

Continue reading Watch out for predatory journals, and consider retract/replace, suggests medical journal group

Major publisher threatened to sue author who didn’t realize he owed open access fees

Around two years ago, when mathematics researcher Jean Ecalle submitted a paper to Acta Mathematica Vietnamica, he saw that he had the option of making the paper open access. So he checked a box on the submission form — which included a mention of the fees that he apparently missed — and didn’t think anything of it.

The paper “Eupolars and their Bialternality Grid” appeared online in October, 2015

So Ecalle was quite surprised when, sometime later, he received an email from a representative of the publisher saying he owed 2,640 Euros. He responded in January 2016, guessing what the fees might stem from:

Continue reading Major publisher threatened to sue author who didn’t realize he owed open access fees

Journal retracts gastric cancer study with multiple duplications, authors MIA

An oncology journal has decided to retract a 2012 paper on gastric cancer after discovering duplicated data in multiple figures.

According to the retraction notice, the journal’s editorial board received a tip from a reader regarding the potential figure issues. Oncology Reports launched an investigation, which confirmed the allegations. The authors failed to respond to the journal’s multiple requests for more information.

Here’s the retraction notice: Continue reading Journal retracts gastric cancer study with multiple duplications, authors MIA

Authors retract tanning-UV radiation study for lacking approval

Researchers have agreed to pull a 2015 study exploring whether a plant extract can safeguard tanners from ultraviolet exposure after not obtaining formal approval from an ethics committee.

According to the first author, the problem lay in a misunderstanding – when they originally applied for approval six years ago, the researchers believed they didn’t need to go through a formal approval process, since the compound was commercially available without a prescription. Once they realized their mistake, they chose to retract the paper.

Here’s the retraction note for “Oral Polypodium leucomotos increases the anti-inflammatory and melanogenic responses of the skin to different modalities of sun exposures: a pilot study,” published in Photodermatology Photoimmunology & PhotomedicineContinue reading Authors retract tanning-UV radiation study for lacking approval